Factor X Inhibitor Profile, Comprehensive
Also known as: Bethesda Titer
Use
Confirmation and characterization of factor X inhibitor
Special Instructions
Not provided.
Limitations
This test may not accurately measure autoimmune inhibitors with second-order kinetics using the Bethesda titer system. The presence of residual coagulation factor activity could potentially result in falsely lowered Bethesda titer results. Additionally, lupus anticoagulant activity and antithrombotic agents functioning as inhibitors should be excluded prior to testing to avoid erroneous results. Some inhibitors may neutralize factors in less than two hours, which is a constraint when interpreting results.
Methodology
Other
Biomarkers
APTT
AnalyteFactor X Activity
Analyte
LOINC Codes
- 14979-9 - aPTT PPP
- 3218-5 - Fact X Act/Nor PPP
- 33356-7 - PT 1h NP Cont PPP
- 33884-8 - PT 1h NP Cont PPP Cont
- 5902-2 - Prothrombin time
- 5959-2 - PT imm NP PPP
- 3216-9 - Fact X Inhib PPP-aCnc
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
6 mL (2 mL in each of three tubes)
Minimum Volume
Not provided
Container
Blue-top (sodium citrate) tubes
Collection Instructions
Citrate plasma samples should be collected by double centrifugation. Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate. Ensure proper blood to anticoagulant ratio and mix by gentle inversion at least six times. Separate using a pipette post-centrifuge and transfer into appropriate transport tubes. Freeze immediately and maintain frozen until testing.
Patient Preparation
Do not draw from an arm with a heparin lock or heparinized catheter.
Storage Instructions
Freeze. Stable at room temperature for four hours.
Other tests from different labs that may be relevant